GeneDx Corp. Statistics
Share Statistics
GeneDx Corp. has 27.47M shares outstanding. The number of shares has increased by 5.44% in one year.
| Shares Outstanding | 27.47M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 1.99% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 21.99M |
| Failed to Deliver (FTD) Shares | 14 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 2.15M, so 7.82% of the outstanding shares have been sold short.
| Short Interest | 2.15M |
| Short % of Shares Out | 7.82% |
| Short % of Float | 9.78% |
| Short Ratio (days to cover) | 4.09 |
Valuation Ratios
The PE ratio is -0.38 and the forward PE ratio is 161.2.
| PE Ratio | -0.38 |
| Forward PE | 161.2 |
| PS Ratio | 0.33 |
| Forward PS | 5 |
| PB Ratio | 0.29 |
| P/FCF Ratio | -0.36 |
| PEG Ratio | n/a |
Enterprise Valuation
GeneDx Corp. has an Enterprise Value (EV) of 86.95M.
| EV / Earnings | -0.49 |
| EV / Sales | 0.43 |
| EV / EBITDA | -0.64 |
| EV / EBIT | -0.53 |
| EV / FCF | -0.47 |
Financial Position
The company has a current ratio of 3.1, with a Debt / Equity ratio of 0.23.
| Current Ratio | 3.1 |
| Quick Ratio | 2.95 |
| Debt / Equity | 0.23 |
| Total Debt / Capitalization | 18.91 |
| Cash Flow / Debt | -3.39 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.77% and return on capital (ROIC) is -46.81%.
| Return on Equity (ROE) | -0.77% |
| Return on Assets (ROA) | -0.37% |
| Return on Capital (ROIC) | -46.81% |
| Revenue Per Employee | 202.57K |
| Profits Per Employee | -175.77K |
| Employee Count | 1K |
| Asset Turnover | 0.43 |
| Inventory Turnover | 16.17 |
Taxes
| Income Tax | -926.00K |
| Effective Tax Rate | 0.01 |
Stock Price Statistics
The stock price has increased by 2065.17% in the last 52 weeks. The beta is 2.18, so GeneDx Corp.'s price volatility has been higher than the market average.
| Beta | 2.18 |
| 52-Week Price Change | 2065.17% |
| 50-Day Moving Average | 77.73 |
| 200-Day Moving Average | 42.62 |
| Relative Strength Index (RSI) | 41.72 |
| Average Volume (20 Days) | 650.62K |
Income Statement
In the last 12 months, GeneDx Corp. had revenue of 202.57M and earned -175.77M in profits. Earnings per share was -7.23.
| Revenue | 202.57M |
| Gross Profit | 60.62M |
| Operating Income | -163.66M |
| Net Income | -175.77M |
| EBITDA | -136.46M |
| EBIT | -163.66M |
| Earnings Per Share (EPS) | -7.23 |
Balance Sheet
The company has 99.68M in cash and 119.77M in debt, giving a net cash position of -20.09M.
| Cash & Cash Equivalents | 99.68M |
| Total Debt | 119.77M |
| Net Cash | -20.09M |
| Retained Earnings | -1.30B |
| Total Assets | 408.84M |
| Working Capital | 108.67M |
Cash Flow
In the last 12 months, operating cash flow was -180.15M and capital expenditures -5.71M, giving a free cash flow of -185.86M.
| Operating Cash Flow | -180.15M |
| Capital Expenditures | -5.71M |
| Free Cash Flow | -185.86M |
| FCF Per Share | -7.64 |
Margins
Gross margin is 29.93%, with operating and profit margins of -80.79% and -86.77%.
| Gross Margin | 29.93% |
| Operating Margin | -80.79% |
| Pretax Margin | -87.23% |
| Profit Margin | -86.77% |
| EBITDA Margin | -67.37% |
| EBIT Margin | -80.79% |
| FCF Margin | -91.75% |
Dividends & Yields
WGS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -10.03% |
| FCF Yield | -9.38% |
Analyst Forecast
The average price target for WGS is $75, which is 4% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $75 |
| Price Target Difference | 4% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
Stock Splits
The last stock split was on May 4, 2023. It was a backward split with a ratio of 1:33.
| Last Split Date | May 4, 2023 |
| Split Type | backward |
| Split Ratio | 1:33 |
Scores
| Altman Z-Score | 2.65 |
| Piotroski F-Score | 3 |